| Sep 27 |
Benitec Non-GAAP EPS of -$5.51
|
| Sep 26 |
Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update
|
| Sep 18 |
Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society
|
| Sep 17 |
Benitec Biopharma CEO to Participate in OPMD Awareness Day Webinar
|
| Jul 15 |
Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study
|
| Jul 1 |
Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors
|
| Jun 13 |
Piper Sandler starts Benitec at overweight, cites BB-301 opportunity
|
